美国NDC复合药物数据库文件

药品名称：商品名称：药品NDC：报告期内： -格式:2020-5-3
NDC包装id：市场分类：活性成分：持证企业：

美国NDC复合药物数据库文件4843条(本栏目更新到2026-3-31)

药品名称(分析)

商品名

药品NDC

专利人(分析)

报告期内

活性成分

市场分类

规格(分析)

NDC包装id

Neostigmine Methylsulfate

HUMAN COMPOUNDED DRUG

71266-2003

Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories

2024-2

NEOSTIGMINE METHYLSULFATE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

1 mg/1 mL

71266-2003-2

Neostigmine Methylsulfate

HUMAN COMPOUNDED DRUG

71266-2003

Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories

2024-2

NEOSTIGMINE METHYLSULFATE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

1 mg/1 mL

71266-2003-1

Ephedrine

HUMAN COMPOUNDED DRUG

71266-9035

Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories

2024-2

EPHEDRINE SULFATE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

10 mg/1 mL

71266-9035-9

Bupivacaine

HUMAN COMPOUNDED DRUG

71266-9160

Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories

2024-2

BUPIVACAINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

2.5 mg/1 mL

71266-9160-2

Diclofenac Sodium

HUMAN COMPOUNDED DRUG

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

100 mg

71300-6727-5

Lidocaine HCl and Bupivacaine HCl

HUMAN COMPOUNDED DRUG

71300-6591

Nubratori Inc.

2024-2

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

3.75 mg/1 mL; 10 mg/1 mL

71300-6591-1

Dexamethasone sodium phosphate

HUMAN COMPOUNDED DRUG

71300-6717

Nubratori Inc.

2024-2

DEXAMETHASONE SODIUM PHOSPHATE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

24 mg/1 mL

71300-6717-1

S-T062.5

HUMAN COMPOUNDED DRUG

79559-1062

F. H. Investments. Inc. DBA Asteria Health

2024-2

TESTOSTERONE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

62.5 mg/62.5 mg

79559-1062-1

S-E037.5

HUMAN COMPOUNDED DRUG

79559-3037

F. H. Investments. Inc. DBA Asteria Health

2024-2

ESTRADIOL

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

37.5 mg/37.5 mg

79559-3037-1

S-TA064

HUMAN COMPOUNDED DRUG

79559-4064

F. H. Investments. Inc. DBA Asteria Health

2024-2

TESTOSTERONE; ANASTROZOLE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

60 mg/64 mg; 4 mg/64 mg

79559-4064-1

S-TA210

HUMAN COMPOUNDED DRUG

79559-4210

F. H. Investments. Inc. DBA Asteria Health

2024-2

TESTOSTERONE; ANASTROZOLE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

200 mg/210 mg; 10 mg/210 mg

79559-4210-1

S-TT100

HUMAN COMPOUNDED DRUG

79559-6100

F. H. Investments. Inc. DBA Asteria Health

2024-2

TESTOSTERONE; TRIAMCINOLONE ACETONIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

100 mg/100 mg; .02 mg/100 mg

79559-6100-1

S-TT087

HUMAN COMPOUNDED DRUG

79559-6087

F. H. Investments. Inc. DBA Asteria Health

2024-2

TESTOSTERONE; TRIAMCINOLONE ACETONIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

87.5 mg/87.5 mg; .0175 mg/87.5 mg

79559-6087-1

141037 HYDROQUINONE 4%//TRETINOIN 0.025%

HUMAN COMPOUNDED DRUG

72934-6380

SKNV

2024-2

HYDROQUINONE; TRETINOIN

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

4 g/100 mL; .025 g/100 mL

72934-6380-2

091052 CLOBETASOL PROPIONATE 0.05% / NIACINAMIDE 4%

HUMAN COMPOUNDED DRUG

72934-4364

SKNV

2024-2

CLOBETASOL PROPIONATE; NIACINAMIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

.05 g/100 mL; 4 g/100 mL

72934-4364-5

091088 CLOBETASOL PROPIONATE 0.05% / NIACINAMIDE 4%

HUMAN COMPOUNDED DRUG

72934-5364

SKNV

2024-2

CLOBETASOL PROPIONATE; NIACINAMIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

.05 g/100 mL; 4 g/100 mL

72934-5364-3

171010 BRIMONIDINE TARTRATE 0.25%

HUMAN COMPOUNDED DRUG

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

.25 g/100 mL

72934-1396-2

171082 BRIMONIDINE TARTRATE 0.25% / IVERMECTIN 1% / METRONIDAZOLE 1% / NIACINAMIDE 4%

HUMAN COMPOUNDED DRUG

72934-1399

SKNV

2024-2

NIACINAMIDE; IVERMECTIN; METRONIDAZOLE; BRIMONIDINE TARTRATE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

4 g/100 mL; 1 g/100 mL; 1 g/100 mL; .25 g/100 mL

72934-1399-2

141030 HYDROQUINONE 8%

HUMAN COMPOUNDED DRUG

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

8 g/100 mL

72934-6379-2

141055 HYDROQUINONE 6%

HUMAN COMPOUNDED DRUG

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

6 g/100 mL

72934-6383-2

网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈

浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　

浙公网安备:330683240604819103159
　医药代理商群１：

医药代理商群２：

医药代理商群３：